MA31517B1 - Sels de l'inhibiteur (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile de la janus kinase - Google Patents
Sels de l'inhibiteur (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile de la janus kinaseInfo
- Publication number
- MA31517B1 MA31517B1 MA32505A MA32505A MA31517B1 MA 31517 B1 MA31517 B1 MA 31517B1 MA 32505 A MA32505 A MA 32505A MA 32505 A MA32505 A MA 32505A MA 31517 B1 MA31517 B1 MA 31517B1
- Authority
- MA
- Morocco
- Prior art keywords
- janus kinase
- cyclopentylpropanenitrile
- pyrrolo
- pyrazol
- pyrimidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
La présente invention concerne des formes de sel de (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile qui se révèlent utiles pour la modulation de l'activité janus kinase et se révèlent utiles pour le traitement de maladies liées à l'activité des janus kinases, notamment des maladies liées à l'immunité, des troubles cutanés, des troubles myéloïdes proliférants, le cancer et d'autres maladies.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94370507P | 2007-06-13 | 2007-06-13 | |
PCT/US2008/066662 WO2008157208A2 (fr) | 2007-06-13 | 2008-06-12 | Sels de l'inhibiteur (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile de la janus kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31517B1 true MA31517B1 (fr) | 2010-07-01 |
Family
ID=40029273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32505A MA31517B1 (fr) | 2007-06-13 | 2010-01-12 | Sels de l'inhibiteur (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile de la janus kinase |
Country Status (42)
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005105814A1 (fr) * | 2004-04-28 | 2005-11-10 | Incyte Corporation | Inhibiteurs tetracycliques de janus kinases |
NZ567851A (en) | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
BRPI0619817B8 (pt) | 2005-12-13 | 2021-05-25 | Incyte Corp | composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição |
US8513270B2 (en) * | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
MX2009013402A (es) | 2007-06-13 | 2010-02-24 | Incyte Corp | Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo. |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
EP2220068B1 (fr) * | 2007-11-16 | 2016-01-27 | Incyte Holdings Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines et 4-pyrazolyl-n-hétéroarylpyrimidin-2-amines en tant qu'inhibiteurs de janus kinase |
NZ587928A (en) * | 2008-03-11 | 2012-08-31 | Incyte Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
JOP20190231A1 (ar) * | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
CN105601619A (zh) | 2009-02-27 | 2016-05-25 | 埃姆比特生物科学公司 | 调控jak激酶的喹唑啉衍生物和其使用方法 |
EP2432472B1 (fr) | 2009-05-22 | 2019-10-02 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- ou heptane-nitrile en tant qu'inhibiteurs de jak |
BRPI1012159B1 (pt) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
ES2435491T3 (es) * | 2009-10-09 | 2013-12-19 | Incyte Corporation | Derivados de hidroxilo, ceto y glucurónido de 3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo |
SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
JP5858434B2 (ja) * | 2010-02-18 | 2016-02-10 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Janusキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体 |
EP4036088B1 (fr) | 2010-03-10 | 2024-04-03 | Incyte Holdings Corporation | Dérivés de pipéridine-4-yl azétidine utilisés en tant qu'inhibiteurs de jak1 |
EP3087972A1 (fr) * | 2010-05-21 | 2016-11-02 | Incyte Holdings Corporation | Formulation topique pour un inhibiteur jak |
KR20130102060A (ko) | 2010-09-01 | 2013-09-16 | 암비트 바이오사이언시즈 코포레이션 | 퀴나졸린 화합물 및 이의 사용 방법 |
DK2635299T3 (da) * | 2010-11-02 | 2019-10-21 | Univ Columbia | Fremgangsmåder til behandling af hårtabsforstyrrelser |
CA2816957A1 (fr) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions et procedes de traitement de la myelofibrose |
JP5917545B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体 |
CA2818545C (fr) | 2010-11-19 | 2019-04-16 | Incyte Corporation | Pyrrolopyridines et pyrrolopyrimidines a substitution heterocyclique utilisees en tant qu'inhibiteurs des jak |
ES2547916T3 (es) * | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
BR112013032125A2 (pt) * | 2011-06-14 | 2016-12-13 | Novartis Ag | combinação de panobinostat e ruxolitinibe no tratamento de câncer do tipo neoplasia mieloproliferativa |
AU2012273164B2 (en) | 2011-06-20 | 2015-05-28 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
WO2013020372A1 (fr) * | 2011-08-09 | 2013-02-14 | 中国科学院上海生命科学研究院 | Méthodes et réactifs pour la prévention et la guérison d'une insulinorésistance et du diabète sucré |
EP2741747A1 (fr) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | Polythérapie par jak p13k/mtor |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
CA3131037A1 (fr) | 2011-11-30 | 2013-06-06 | Emory University | Inhibiteurs de jak antiviraux utiles dans le traitement ou la prevention d'infections retrovirales et autres infections virales |
WO2013173506A2 (fr) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Procédé de traitement d'une dégradation musculaire |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
WO2014013014A1 (fr) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Inhibiteurs de jak pour l'activation de populations de cellules souches épidermiques |
CA2879603A1 (fr) | 2012-07-27 | 2014-01-30 | Ratiopharm Gmbh | Formes galeniques orales destinees a une liberation modifiee comprenant du ruxolitinib |
KR20150074193A (ko) | 2012-11-01 | 2015-07-01 | 인사이트 코포레이션 | Jak 억제제로서 트리사이클릭 융합된 티오펜 유도체 |
IL291391B (en) | 2012-11-15 | 2022-11-01 | Incyte Holdings Corp | Sustained release dosage forms of roxolitinib |
PT2964650T (pt) | 2013-03-06 | 2019-02-26 | Incyte Holdings Corp | Processos e intermediários para a preparação de um inibidor de jak |
US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
SI3527263T1 (sl) | 2013-05-17 | 2021-05-31 | Incyte Corporation | Derivati bipirazola kot zaviralci JAK |
MX2016001639A (es) | 2013-08-07 | 2016-10-07 | Incyte Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
WO2015040243A2 (fr) * | 2013-09-23 | 2015-03-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pour cibler un microenvironnement de tumeur et pour prévenir la métastase |
LT3129021T (lt) | 2014-04-08 | 2020-12-10 | Incyte Corporation | B ląstelių piktybiškumo gydymas jak ir pi3k inhibitorių deriniu |
AU2015253192B2 (en) | 2014-04-30 | 2019-05-16 | Incyte Holdings Corporation | Processes of preparing a JAK1 inhibitor and new forms thereto |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
CN105218548A (zh) * | 2014-06-09 | 2016-01-06 | 上海海和药物研究开发有限公司 | 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途 |
DK3179992T3 (da) | 2014-08-11 | 2022-07-11 | Acerta Pharma Bv | Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor |
HUE056329T2 (hu) | 2014-08-11 | 2022-02-28 | Acerta Pharma Bv | BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi |
US20170224819A1 (en) | 2014-08-11 | 2017-08-10 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor |
ES2874537T3 (es) * | 2014-08-21 | 2021-11-05 | Ratiopharm Gmbh | Sal oxalato de ruxolitinib |
WO2016026975A1 (fr) * | 2014-08-21 | 2016-02-25 | Ratiopharm Gmbh | Sel de (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile avec de l'acide benzènesulfonique |
WO2016035014A1 (fr) * | 2014-09-01 | 2016-03-10 | Sun Pharmaceutical Industries Limited | Procédés de préparation d'énamines |
WO2016063294A2 (fr) * | 2014-10-20 | 2016-04-28 | Msn Laboratories Private Limited | Procédé de préparation de phosphate de (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile et de ses polymorphes |
CZ2014773A3 (cs) | 2014-11-10 | 2016-05-18 | Zentiva, K.S. | Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu |
US20170335324A1 (en) | 2014-11-12 | 2017-11-23 | The General Hospital Corporation | Methods for treating neurodegenerative diseases |
CZ2015496A3 (cs) | 2015-07-14 | 2017-01-25 | Zentiva, K.S. | Krystalické formy solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a jejich příprava |
EP4079320A1 (fr) | 2016-01-12 | 2022-10-26 | Inc. Oncotracker | Procédés améliorés de surveillance de l'état immunitaire d'un sujet |
CZ201629A3 (cs) | 2016-01-22 | 2017-08-02 | Zentiva, K.S. | Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy |
CN107573348B (zh) * | 2016-01-29 | 2019-09-03 | 上海宣创生物科技有限公司 | 巴瑞克替尼三氟乙酸盐b晶型及其制备方法 |
CN105601635B (zh) * | 2016-02-01 | 2017-12-12 | 上海宣创生物科技有限公司 | 巴瑞克替尼磷酸盐的a晶型、h晶型和i晶型及其制备方法 |
US20200308240A1 (en) * | 2016-04-01 | 2020-10-01 | The General Hospital Corporation | Targeting Innate Immune Signaling in Neuroinflammation and Neurodegeneration |
CN107759600A (zh) * | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
WO2018041989A1 (fr) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de diagnostic et de traitement de la maladie coeliaque réfractaire de type 2 |
RU2644155C1 (ru) * | 2016-12-12 | 2018-02-08 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | 2-(3-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)-1H-пиразол-1-ил)-1-(этилсульфонил)азетидин-3-ил)ацетонитрила геминафтилдисульфонат в качестве ингибитора Янус киназ |
US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
EP3710431A4 (fr) * | 2017-11-03 | 2021-07-07 | Aclaris Therapeutics, Inc. | Inhibiteurs de jak à base de pyrrolopyrimidine substituée et leurs procédés de fabrication et d'utilisation |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
RS63312B1 (sr) | 2018-01-30 | 2022-07-29 | Incyte Corp | Procesi za pripremu (1-(3-fluoro-2-(trifluorometil)izonikotinil)piperidin-4-on) |
CN111936135A (zh) | 2018-02-16 | 2020-11-13 | 因赛特公司 | 用于治疗细胞因子相关的病症的jak1通路抑制剂 |
CA3092931A1 (fr) | 2018-03-08 | 2019-09-12 | Novartis Ag | Utilisation d'un anticorps anti-p-selectine |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
JP2021519772A (ja) | 2018-03-30 | 2021-08-12 | インサイト・コーポレイションIncyte Corporation | 炎症性皮膚疾患のバイオマーカー |
EP3775923A1 (fr) | 2018-04-13 | 2021-02-17 | Incyte Corporation | Biomarqueurs pour une maladie du greffon contre l'hôte |
CN113194928A (zh) | 2018-07-31 | 2021-07-30 | 罗索肿瘤学公司 | (s)-5-氨基-3-(4-((5-氟-2-甲氧基苯甲酰胺基)甲基)苯基)-1-(1,1,1-三氟丙-2-基)-1h-吡唑-4-甲酰胺的喷雾干燥的分散体和制剂 |
JP2021534244A (ja) | 2018-08-10 | 2021-12-09 | アクラリス セラピューティクス,インコーポレイテッド | ピロロピリミジンitk阻害剤 |
WO2020039401A1 (fr) | 2018-08-24 | 2020-02-27 | Novartis Ag | Traitement comprenant des anticorps se liant à il-1 βeta et ses combinaisons |
AR116114A1 (es) | 2018-09-04 | 2021-03-31 | Theravance Biopharma R&D Ip Llc | Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak |
CA3117969A1 (fr) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Polytherapie pour le traitement de maladies hematologiques |
US20220041579A1 (en) | 2018-12-19 | 2022-02-10 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases |
WO2020131627A1 (fr) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Composés pyrazolo[1,5-a]pyridine substitués servant d'inhibiteurs de tyrosine kinases fgfr |
EP3934651A1 (fr) | 2019-03-05 | 2022-01-12 | Incyte Corporation | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
WO2020201362A2 (fr) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes |
EP3955920A1 (fr) | 2019-04-16 | 2022-02-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Utilisation d'inhibiteurs de jak pour le traitement d'états douloureux impliquant des canaux nav1.7 |
KR20220004726A (ko) | 2019-05-02 | 2022-01-11 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | Jak 억제제로서의 치환된 피롤로피리딘 |
US11602536B2 (en) | 2019-06-10 | 2023-03-14 | Incyte Corporation | Topical treatment of vitiligo by a JAK inhibitor |
WO2020261219A1 (fr) | 2019-06-27 | 2020-12-30 | Crispr Therapeutics Ag | Utilisation de lymphocytes t récepteurs d'antigènes chimériques et d'inhibiteurs de cellules nk pour le traitement du cancer |
CN114599364A (zh) | 2019-09-05 | 2022-06-07 | 因赛特公司 | 用于减少特应性皮炎瘙痒的鲁索替尼制剂 |
CN114450008A (zh) | 2019-09-16 | 2022-05-06 | 诺华股份有限公司 | Mdm2抑制剂用于治疗骨髓纤维化的用途 |
JP2022548627A (ja) | 2019-09-16 | 2022-11-21 | ノバルティス アーゲー | 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗t細胞免疫グロブリンドメイン及びムチンドメイン3(tim-3)igg4抗体の使用 |
WO2021076124A1 (fr) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Utilisation d'inhibiteurs de jak1 pour le traitement du lupus érythémateux cutané et du lichen plan (l.p.) |
US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
CN115038443A (zh) | 2019-11-22 | 2022-09-09 | 因西特公司 | 包含alk2抑制剂和jak2抑制剂的组合疗法 |
WO2021206766A1 (fr) | 2020-04-09 | 2021-10-14 | Children's Hospital Medical Center | Biomarqueurs d'infection par sras-cov-2 et leurs utilisations |
US11324750B2 (en) | 2020-04-09 | 2022-05-10 | Children's Hospital Medical Center | Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection |
EP3892280A3 (fr) | 2020-04-09 | 2022-01-12 | Children's Hospital Medical Center | Biomarqueurs d'une infection sars-cov-2 et leurs utilisations |
PE20231102A1 (es) | 2020-06-02 | 2023-07-19 | Incyte Corp | Procesos para preparar un inhibidor de jak1 |
JP2023529365A (ja) | 2020-06-03 | 2023-07-10 | インサイト・コーポレイション | 骨髄増殖性腫瘍の治療のための、ルキソリチニブとincb057643との組合わせ |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2021260657A1 (fr) | 2020-06-26 | 2021-12-30 | Crispr Therapeutics Ag | Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19 |
KR20230095923A (ko) | 2020-08-18 | 2023-06-29 | 인사이트 코포레이션 | Jak1 억제제를 제조하기 위한 공정 및 중간체 |
PE20231743A1 (es) | 2020-08-18 | 2023-10-31 | Incyte Corp | Proceso e intermediarios para preparar un inhibidor de jak |
CA3195357A1 (fr) | 2020-09-16 | 2022-03-24 | Incyte Corporation | Traitement topique du vitiligo |
JP2023544728A (ja) | 2020-10-02 | 2023-10-25 | インサイト・コーポレイション | 扁平苔癬の治療のための局所ルキソリチニブ |
TW202227076A (zh) | 2020-10-08 | 2022-07-16 | 瑞士商諾華公司 | Erk抑制劑用於治療骨髓纖維化之用途 |
US20240000777A1 (en) | 2020-10-08 | 2024-01-04 | Novartis Ag | Use of an erk inhibitor for the treatment of myelofibrosis |
AU2021390533A1 (en) | 2020-12-04 | 2023-06-29 | Incyte Corporation | Jak inhibitor with a vitamin d analog for treatment of skin diseases |
TW202237089A (zh) | 2020-12-08 | 2022-10-01 | 美商英塞特公司 | 用於治療白斑病之jak1途徑抑制劑 |
US11918581B2 (en) | 2021-01-11 | 2024-03-05 | Incyte Corporation | Combination therapy comprising JAK pathway inhibitor and rock inhibitor |
CA3206708A1 (fr) | 2021-02-25 | 2022-09-01 | Ida ARONCHIK | Utilisation d'un inhibiteur de bet seul ou en combinaison avec du fedratinib ou du ruxolitinib pour le traitement d'une malignite hematologique telle que la myelofibrose |
WO2023102559A1 (fr) | 2021-12-03 | 2023-06-08 | Incyte Corporation | Formulations topiques de ruxolitinib avec un agent d'ajustement du ph à base d'amine organique pour le traitement de maladies de la peau |
WO2023222565A1 (fr) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Procédés d'évaluation de l'épuisement de cellules souches hématopoïétiques induites par une inflammation chronique |
US20230399331A1 (en) | 2022-06-14 | 2023-12-14 | Incyte Corporation | Solid forms of jak inhibitor and process of preparing the same |
WO2024028193A1 (fr) | 2022-08-03 | 2024-02-08 | Medichem, S.A. | Formulation pharmaceutique orale stable contenant de l'hémifumarate de ruxolitinib |
WO2024099396A1 (fr) * | 2022-11-11 | 2024-05-16 | 浙江奥翔药业股份有限公司 | Cristal de ruxolitinib et composition pharmaceutique de celui-ci |
Family Cites Families (286)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2985589A (en) | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
US3832460A (en) * | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
GB2030584B (en) | 1978-10-03 | 1983-03-23 | Lankro Chem Ltd | Photopolymerisable solder resist compositions |
JPS5553537A (en) | 1978-10-13 | 1980-04-19 | Barron Robert Michael | Abrasive foam material and its preparation |
DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
DE3220113A1 (de) | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | Difluormethoxiphenylthiophosphorsaeureester |
US4402832A (en) | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
US4498991A (en) | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
NL8403224A (nl) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
CA1306260C (fr) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Derives imidazopyridine condenses |
JPH0781138B2 (ja) | 1986-12-02 | 1995-08-30 | 株式会社資生堂 | 抗酸化剤 |
ES2087916T3 (es) | 1989-10-11 | 1996-08-01 | Teijin Ltd | Derivado de pirimidina biciclico, metodo para producir el mismo, y preparacion farmaceutica que contiene el mismo como ingrediente activo. |
IT1258781B (it) | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
US6638905B2 (en) | 1993-06-18 | 2003-10-28 | The Salk Institute For Biological Studies | Cloning and recombinant production of CFR receptor(s) |
JPH0710876A (ja) | 1993-06-24 | 1995-01-13 | Teijin Ltd | 4位に環状アミノ基を有するピロロ[2,3―d]ピリミジン |
EP0727217A3 (fr) | 1995-02-10 | 1997-01-15 | Suntory Ltd | Compositions pharmaceutiques et cosmétiques contenant ellagitannin du type god comme principe actif |
IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
BR9609613A (pt) | 1995-07-05 | 1999-05-25 | Du Pont | Composto composição fungicida e método de controle de doenças de plantas |
HUP9900330A3 (en) | 1995-07-06 | 2001-08-28 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5630943A (en) | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
AU727939B2 (en) | 1996-04-03 | 2001-01-04 | Merck & Co., Inc. | A method of treating cancer |
EP0952842A2 (fr) | 1996-04-18 | 1999-11-03 | Merck & Co., Inc. | Methode de traitement de cancer |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
AU3215197A (en) | 1996-05-30 | 1998-01-05 | Merck & Co., Inc. | A method of treating cancer |
US6624138B1 (en) * | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
WO1998044797A1 (fr) | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | Procede de traitement du cancer |
US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
US6063284A (en) | 1997-05-15 | 2000-05-16 | Em Industries, Inc. | Single column closed-loop recycling with periodic intra-profile injection |
US5919779A (en) | 1997-08-11 | 1999-07-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,6-Heteroaryl-dipyrido(2,3-B:3', 2'-F) azepines and their use in the prevention or treatment of HIV infection |
US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
KR20010052570A (ko) | 1998-06-04 | 2001-06-25 | 스티븐 에프. 웨인스톡 | 세포 유착을 억제하는 소염성 화합물 |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
AU3951899A (en) | 1998-06-19 | 2000-01-05 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
CA2339961C (fr) | 1998-08-11 | 2009-01-20 | Novartis Ag | Derives d'isoquinoline possedant une activite d'inhibition de l'angiogenese |
JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
ES2190241T3 (es) * | 1998-09-10 | 2003-07-16 | Nycomed Danmark As | Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas. |
JP3869128B2 (ja) | 1998-09-11 | 2007-01-17 | 株式会社ルネサステクノロジ | 半導体集積回路装置の製造方法 |
US6375839B1 (en) | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
US6413419B1 (en) | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
FR2785196B1 (fr) | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | Procede et dispositif de separation avec des zones chromatographiques a longueur variable |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
EP1165084A4 (fr) | 1999-03-03 | 2002-05-15 | Merck & Co Inc | Inhibiteurs de prenyl-proteine transferases |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
AU3565999A (en) | 1999-04-16 | 2000-11-02 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
WO2001027104A1 (fr) | 1999-10-13 | 2001-04-19 | Banyu Pharmaceutical Co., Ltd. | Derives d'imidazolidinone a substitution |
PT1235830E (pt) * | 1999-12-10 | 2004-04-30 | Pfizer Prod Inc | Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases |
MXPA02006338A (es) * | 1999-12-24 | 2002-12-13 | Aventis Pharma Ltd | Azaindoles. |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
DE60100866T2 (de) | 2000-04-07 | 2004-07-29 | Laboratoire Medidom S.A. | Cyklosporin, Hyaluronsäure und Polysorbate enthaltenes Augenarzneimittel |
WO2001081345A1 (fr) | 2000-04-20 | 2001-11-01 | Mitsubishi Pharma Corporation | Composes d'amides aromatiques |
IL152275A0 (en) | 2000-04-25 | 2003-05-29 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
WO2001098344A2 (fr) | 2000-06-16 | 2001-12-27 | Curis, Inc. | Compositions modulatrices de l'angiogenese et leurs utilisations |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
US6335342B1 (en) * | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
CA2413313C (fr) * | 2000-06-23 | 2011-06-14 | Mitsubishi Pharma Corporation | Potentialisateurs d'effet antitumoral |
PL359563A1 (en) | 2000-06-26 | 2004-08-23 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
BR0111747A (pt) | 2000-06-28 | 2003-07-08 | Smithkline Beecham Plc | Processo de moagem úmida |
CA2430539C (fr) | 2000-12-05 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de kinases c-jun n-terminales (jnk) et d'autres proteines kinases |
GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
WO2002055496A1 (fr) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Derives aryle de piperidine et de piperazine comme inducteurs de l'expression du recepteur ldl |
WO2002060492A1 (fr) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Procedes d'inhibition de kinases |
WO2002092573A2 (fr) | 2001-05-16 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de src et autres proteine kinases |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
US6852727B2 (en) * | 2001-08-01 | 2005-02-08 | Merck & Co., Inc. | Benzimisazo[4,5-f]isoquinolinone derivatives |
AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
US6429231B1 (en) | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
CN101703509A (zh) | 2001-10-30 | 2010-05-12 | 诺瓦提斯公司 | 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物 |
JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
AU2002224131A1 (en) | 2001-11-30 | 2003-06-17 | Teijin Limited | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
EP1506189A1 (fr) * | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Derives de pyrrole utilises en tant qu'inhibiteurs de erk2 et leurs utilisations |
AU2003241326B2 (en) | 2002-05-02 | 2008-05-01 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
JP2005532313A (ja) | 2002-05-07 | 2005-10-27 | コントロール・デリバリー・システムズ・インコーポレイテッド | 薬物送達装置の形成方法 |
US7122550B2 (en) | 2002-05-23 | 2006-10-17 | Cytopia Pty Ltd | Protein kinase inhibitors |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
EP1535934A4 (fr) | 2002-06-26 | 2005-11-02 | Idemitsu Kosan Co | Copolymere hydrogene, son procede de production et composition d'adhesif thermofusible le contenant |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
WO2004007472A1 (fr) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Antagoniste du ccr4 et utilisation medicinale correspondante |
EP1542768A1 (fr) | 2002-09-20 | 2005-06-22 | Alcon, Inc. | Utilisation d'inhibiteurs de la synthese des cytokines dans le traitement des troubles associes a la keratoconjonctivite seche |
US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
JP4688498B2 (ja) | 2002-11-04 | 2011-05-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Jakインヒビターとしてのヘテロアリール−ピリミジン誘導体 |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
MXPA05005576A (es) | 2002-11-26 | 2005-07-27 | Pfizer Prod Inc | Procedimiento de tratamiento del rechazo a un trasplante. |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
TWI335819B (en) | 2002-12-24 | 2011-01-11 | Alcon Inc | Use of oculosurface selective glucocorticoid in the treatment of dry eye |
US7135493B2 (en) | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
US7167750B2 (en) * | 2003-02-03 | 2007-01-23 | Enteromedics, Inc. | Obesity treatment with electrically induced vagal down regulation |
US7407962B2 (en) | 2003-02-07 | 2008-08-05 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors or protein kinases |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
CA2522595A1 (fr) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions utiles en tant qu'inhibiteurs de proteines kinases |
SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
FR2857454B1 (fr) | 2003-07-08 | 2006-08-11 | Aventis Pasteur | Dosage des acides techoiques des bacteries gram+ |
US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
CN1870997B (zh) | 2003-10-24 | 2011-05-04 | 参天制药株式会社 | 角膜结膜病变的治疗剂 |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
BRPI0416909A (pt) | 2003-11-25 | 2007-01-16 | Pfizer Prod Inc | método de tratamento de aterosclerose |
WO2005060972A2 (fr) | 2003-12-17 | 2005-07-07 | Pfizer Products Inc. | Methode pour traiter le rejet de greffe |
ATE406356T1 (de) | 2003-12-19 | 2008-09-15 | Schering Corp | Thiadiazole als cxc- und cc- chemokinrezeptorliganden |
PT1696920E (pt) | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
NZ547696A (en) | 2003-12-23 | 2009-12-24 | Astex Therapeutics Ltd | Pyrazole derivatives as protein kinase modulators |
WO2005067546A2 (fr) * | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Derives et analogues de pyrrolopyrimidine et utilisation de ceux-ci dans le traitement a la prevention de maladies |
CA2559285A1 (fr) | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Traitement des synucleinopathies |
TWI471133B (zh) | 2004-03-30 | 2015-02-01 | Vertex Pharma | 適合作為jak及其它蛋白質激酶抑制劑之氮雜吲哚 |
EP1750727A2 (fr) | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Modulateurs des proteines kinases et leurs methodes d'utilisation |
WO2005105814A1 (fr) * | 2004-04-28 | 2005-11-10 | Incyte Corporation | Inhibiteurs tetracycliques de janus kinases |
WO2005105988A2 (fr) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Structure cristalline de complexe de domaine jak3 kinase humaine et ses poches de liaison |
US20090163523A1 (en) | 2004-05-03 | 2009-06-25 | Philip Lake | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor |
CA2566158A1 (fr) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Inhibiteurs de kinases en tant qu'agents therapeutiques |
PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
RU2401265C2 (ru) | 2004-06-10 | 2010-10-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
WO2006004984A1 (fr) | 2004-06-30 | 2006-01-12 | Vertex Pharmaceuticals Incorporated | Azaindoles utilises comme inhibiteurs de proteine kinases |
US7138423B2 (en) * | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
FR2873691B1 (fr) | 2004-07-29 | 2006-10-06 | Sanofi Synthelabo | Derives d'amino-piperidine, leur preparation et leur application en therapeutique |
WO2006013114A1 (fr) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Utilisation d'un produit proteique timp-2 secrete pour la prevention et le traitement d'affections du pancreas, de l'obesite et/ou du syndrome metabolique |
CN101006186A (zh) | 2004-08-23 | 2007-07-25 | 财团法人牧岩生命工学研究所 | 用于检测sars冠状病毒的引物和探针,包括该引物和/或探针的试剂盒及其检测方法 |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
DK1802625T3 (da) | 2004-10-13 | 2008-09-01 | Hoffmann La Roche | Disubstituerede pyrazolobenzodiazepiner der er nyttige som inhibitorer af CDK2 og angiogenese og til behandling af bryst-, tyktarms-, lunge- og prostatacancer |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
US7528138B2 (en) | 2004-11-04 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
CA2586605A1 (fr) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinaisons d'inhibiteurs de kinase jak |
US7517870B2 (en) | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
WO2006065916A1 (fr) | 2004-12-14 | 2006-06-22 | Alcon, Inc. | Procede de traitement des troubles associes a la keratoconjonctivite seche par le 13(s)-hode et ses analogues |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
TW200635899A (en) | 2004-12-22 | 2006-10-16 | Astrazeneca Ab | Chemical compounds |
EP1844037A1 (fr) | 2005-01-20 | 2007-10-17 | Pfizer Limited | Composes chimiques |
RU2434871C2 (ru) * | 2005-02-03 | 2011-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиримидины, применимые в качестве ингибиторов протеинкиназы |
US7683171B2 (en) | 2005-02-04 | 2010-03-23 | Bristol-Myers Squibb Company | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
KR20070119690A (ko) | 2005-03-15 | 2007-12-20 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
AU2006232105A1 (en) | 2005-04-05 | 2006-10-12 | Pharmacopeia, Inc. | Purine and imidazopyridine derivatives for immunosuppression |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
ZA200710379B (en) | 2005-05-20 | 2009-05-27 | Vertex Pharma | Pyrrolopyridines useful as inhibitors of protein kinase |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CA2608367C (fr) | 2005-06-08 | 2014-08-19 | Rigel Pharmaceuticals, Inc. | Compositions et procedes d'inhibition de la voie jak |
NZ563984A (en) | 2005-06-08 | 2011-11-25 | Targegen Inc | Methods and compositions for the treatment of ocular disorders |
WO2006136823A1 (fr) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Amine contenant des heterocycliques comme inhibiteurs des kinases b |
HUE027370T2 (en) | 2005-06-22 | 2016-10-28 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
JP2007010876A (ja) | 2005-06-29 | 2007-01-18 | Fujinon Corp | レンズ駆動装置 |
EP2251341A1 (fr) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Hétérocycles inhibiteurs de Janus kinase-3 |
FR2889662B1 (fr) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
EP2270014A1 (fr) * | 2005-09-22 | 2011-01-05 | Incyte Corporation | Inhibiteurs de l'azépine de janus kinases |
ES2401192T3 (es) | 2005-09-30 | 2013-04-17 | Vertex Pharmceuticals Incorporated | Deazapurinas útiles como inhibidores de janus cinasas |
US20070128633A1 (en) | 2005-10-11 | 2007-06-07 | Chembridge Research Laboratories, Inc. | Cell-free protein expression systems and methods of use thereof |
WO2007043677A1 (fr) | 2005-10-14 | 2007-04-19 | Sumitomo Chemical Company, Limited | Dérivé d'hydrazide et son utilisation en tant que pesticide |
EP1945631B8 (fr) | 2005-10-28 | 2013-01-02 | AstraZeneca AB | Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu' inhibiteurs de tyrosine kinases dans le cadre d un traitement anticancereux |
NZ567851A (en) | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007062459A1 (fr) | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Inhibiteurs selectifs de la kinase a base d’un squelette de pyridine |
BRPI0619817B8 (pt) | 2005-12-13 | 2021-05-25 | Incyte Corp | composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição |
US20130137681A1 (en) | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
WO2007076423A2 (fr) | 2005-12-22 | 2007-07-05 | Smithkline Beecham Corporation | INHIBITEURS D’ACTIVITE Akt |
MX2008008320A (es) | 2005-12-23 | 2008-09-03 | Smithkline Beecham Corp | Inhibidores de azaindol de aurora cinasas. |
AU2007207533B8 (en) | 2006-01-17 | 2012-06-28 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of Janus kinases |
EP1979353A2 (fr) * | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Inhibiteurs de kinase heterobicycliques fusionnes |
JP2009525350A (ja) | 2006-02-01 | 2009-07-09 | スミスクライン ビーチャム コーポレーション | Rafキナーゼ阻害薬として有用なピロロ[2,3,b]ピリジン誘導体 |
US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
EP1995246A4 (fr) | 2006-03-10 | 2010-11-17 | Ono Pharmaceutical Co | Derive heterocyclique azote et agent pharmaceutique comprenant le derive en tant que principe actif |
WO2007116866A1 (fr) | 2006-04-03 | 2007-10-18 | Astellas Pharma Inc. | Compose hetero |
RU2008143361A (ru) | 2006-04-05 | 2010-05-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Деазапурины в качестве ингибиторов янус-киназ |
JP2009533416A (ja) | 2006-04-12 | 2009-09-17 | ファイザー・リミテッド | ケモカインccr5受容体の調節剤としてのピロリジン誘導体 |
WO2007129195A2 (fr) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazoles |
US7691811B2 (en) | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
WO2008011557A2 (fr) | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Inhibiteurs hétéroaryliques de la kinase rho |
WO2008013622A2 (fr) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Amides azocycliques fongicides |
US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
CA2660560A1 (fr) | 2006-08-16 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Composes de pyrazine, leur utilisation et procedes de preparation |
MX2009002558A (es) | 2006-09-08 | 2009-03-20 | Novartis Ag | Derivados de n-biaril-(hetero)-aril-sulfonamida utiles en el tratamiento de enfermedades mediadas por las interacciones de los linfocitos. |
WO2008035376A2 (fr) | 2006-09-19 | 2008-03-27 | Council Of Scientific & Industrial Research | Nouvel insert bio-érodable pour applications ophtalmiques et procédé de préparation correspondant |
AR063141A1 (es) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion |
TW200831104A (en) | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
MX2009004700A (es) | 2006-11-06 | 2009-05-15 | Supergen Inc | Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa. |
US20080119496A1 (en) | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
MX2009005144A (es) | 2006-11-22 | 2009-05-27 | Incyte Corp | Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa. |
WO2008067119A2 (fr) | 2006-11-27 | 2008-06-05 | Smithkline Beecham Corporation | Nouveaux composés |
WO2008076356A1 (fr) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Composés d'oxadiazole innovants |
AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
US8338455B2 (en) | 2006-12-20 | 2012-12-25 | Amgen Inc. | Compounds and methods of use |
US8389014B2 (en) | 2006-12-22 | 2013-03-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
US8513270B2 (en) * | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
WO2008082839A2 (fr) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Inhibiteurs de la pim kinase comme agents chimiothérapeutiques destinés à lutter contre le cancer |
KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
WO2008082840A1 (fr) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Inhibiteurs de la pim kinase utilisés comme agents chimiothérapeutiques contre le cancer |
KR101514853B1 (ko) | 2007-03-01 | 2015-04-24 | 노파르티스 아게 | Pim 키나제 억제제 및 이들의 사용 방법 |
US8138181B2 (en) | 2007-04-03 | 2012-03-20 | Array Biopharma Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
EP2155689B1 (fr) | 2007-05-31 | 2015-07-08 | Boehringer Ingelheim International GmbH | Antagonistes du récepteur ccr2 et leurs utilisations |
GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
MX2009013402A (es) | 2007-06-13 | 2010-02-24 | Incyte Corp | Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo. |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
KR101258316B1 (ko) | 2007-07-11 | 2013-04-30 | 화이자 인코포레이티드 | 안구 건조증 치료용 약학 조성물 및 방법 |
KR20100038119A (ko) | 2007-08-01 | 2010-04-12 | 화이자 인코포레이티드 | 피라졸 화합물 및 raf 억제제로서 이의 용도 |
WO2009049028A1 (fr) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Composés de pyrrolopyrimidine et leur utilisation en tant qu'inhibiteurs des janus kinases |
CA2743756A1 (fr) | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibiteurs de proteines kinases pim, compositions et procedes pour traiter le cancer |
EP2220068B1 (fr) * | 2007-11-16 | 2016-01-27 | Incyte Holdings Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines et 4-pyrazolyl-n-hétéroarylpyrimidin-2-amines en tant qu'inhibiteurs de janus kinase |
GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
SI2231689T1 (sl) | 2008-01-18 | 2016-11-30 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Novi citostatski 7-deazapurinski nukleozidi |
EA019309B1 (ru) | 2008-02-04 | 2014-02-28 | Меркьюри Терапьютикс, Инк. | Модуляторы ampk (амф-активируемой протеинкиназы) |
AR070531A1 (es) | 2008-03-03 | 2010-04-14 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso |
NZ587928A (en) | 2008-03-11 | 2012-08-31 | Incyte Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
WO2009115572A2 (fr) | 2008-03-21 | 2009-09-24 | Novartis Ag | Nouveaux composés hétérocycliques et leurs utilisations |
JP2011526302A (ja) | 2008-06-26 | 2011-10-06 | アンテリオス, インコーポレイテッド | 経皮送達 |
UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
FR2933409B1 (fr) | 2008-07-03 | 2010-08-27 | Centre Nat Rech Scient | NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為pim激酶抑制劑之三唑吡啶化合物 |
US8557809B2 (en) | 2008-08-19 | 2013-10-15 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
BRPI0917459B1 (pt) | 2008-08-20 | 2017-09-12 | Zoetis Services Llc | N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide |
PT2344474E (pt) | 2008-09-02 | 2015-12-28 | Novartis Ag | Derivados de picolinamida como inibidores de cinase |
US8759338B2 (en) | 2008-09-02 | 2014-06-24 | Novartis Ag | Heterocyclic kinase inhibitors |
EP2342190A1 (fr) | 2008-09-02 | 2011-07-13 | Novartis AG | Inhibiteurs bicycliques des kinases |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
EP2210890A1 (fr) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Dérivés d'oxadiazoles en tant qu'agonistes du récepteur S1P1 |
US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
BRPI1012159B1 (pt) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos |
EP2432472B1 (fr) | 2009-05-22 | 2019-10-02 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- ou heptane-nitrile en tant qu'inhibiteurs de jak |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
EP2470534A4 (fr) | 2009-08-24 | 2013-02-27 | Merck Sharp & Dohme | L'inhibition de jak bloque les toxicités associées à l'arn d'interférence |
TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
JP5567136B2 (ja) | 2009-09-08 | 2014-08-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 4−置換ピリジン−3−イル−カルボキサミド化合物及び使用方法 |
EP2305660A1 (fr) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | Nouveaux dérivés de thiadiazole |
ES2435491T3 (es) | 2009-10-09 | 2013-12-19 | Incyte Corporation | Derivados de hidroxilo, ceto y glucurónido de 3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo |
CN102666545B (zh) | 2009-10-20 | 2016-04-06 | 塞尔卓姆有限公司 | 作为jak抑制剂的杂环吡唑并嘧啶类似物 |
EP2332917B1 (fr) | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Composés pour l'inhibition de kinase PIM et pour le traitement des tumeurs |
WO2011066374A2 (fr) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonistes de l'il-6 destinés à prévenir ou à traiter la cachexie, la faiblesse, la fatigue, et/ou la fièvre |
WO2011069141A2 (fr) | 2009-12-04 | 2011-06-09 | Board Of Regents, The University Of Texas System | Traitement à l'interféron en combinaison avec un blocage de l'activation de stat3 |
RU2012132278A (ru) | 2010-01-12 | 2014-02-20 | Ф. Хоффманн-Ля Рош Аг | Трициклические гетероциклические соединения, содержащие их композиции и способы их применения |
SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
JP5858434B2 (ja) | 2010-02-18 | 2016-02-10 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Janusキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体 |
EP4036088B1 (fr) | 2010-03-10 | 2024-04-03 | Incyte Holdings Corporation | Dérivés de pipéridine-4-yl azétidine utilisés en tant qu'inhibiteurs de jak1 |
KR20130094710A (ko) | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Jak 키나아제의 억제제로서 5,7-치환된-이미다조[1,2-c]피리미딘 |
EP2390252A1 (fr) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | Nouveaux dérivés de pyrazole |
EP3087972A1 (fr) | 2010-05-21 | 2016-11-02 | Incyte Holdings Corporation | Formulation topique pour un inhibiteur jak |
US8637529B2 (en) | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
WO2012003457A1 (fr) | 2010-07-01 | 2012-01-05 | Mtm Research Llc | Thérapies au moyen d'émulsions fluorochimiques antifibroblastiques |
WO2012045020A1 (fr) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combinaisons de 4-(cyclopropylamino)-2-(4-(4-(éthylsulfonyl)pipérazin-1-yl)phénylamino)pyrimidine-5-carboxamide et de fludarabine |
CN101974161B (zh) | 2010-09-30 | 2012-10-31 | 中国科学院西双版纳热带植物园 | 一种溶解和快速水解木质纤维素生物质的方法及其设备和应用 |
JP5917545B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体 |
CA2818545C (fr) | 2010-11-19 | 2019-04-16 | Incyte Corporation | Pyrrolopyridines et pyrrolopyrimidines a substitution heterocyclique utilisees en tant qu'inhibiteurs des jak |
EA201390815A1 (ru) | 2010-12-03 | 2013-12-30 | Им Байосайенсиз Острелиа Пти Лтд. | Лечение jak2-опосредованных состояний |
ES2547916T3 (es) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
AU2012273164B2 (en) | 2011-06-20 | 2015-05-28 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
EP2741747A1 (fr) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | Polythérapie par jak p13k/mtor |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
WO2014036016A1 (fr) | 2012-08-31 | 2014-03-06 | Principia Biopharma Inc. | Dérivés de benzimidazole en tant qu'inhibiteurs d'itk |
US9263059B2 (en) | 2012-09-28 | 2016-02-16 | International Business Machines Corporation | Deep tagging background noises |
US20140095210A1 (en) | 2012-10-02 | 2014-04-03 | CareRev, Inc. | Computer-implemented method and system for facilitating information sharing, communication, and collaboration in a healthcare facility |
KR20150074193A (ko) | 2012-11-01 | 2015-07-01 | 인사이트 코포레이션 | Jak 억제제로서 트리사이클릭 융합된 티오펜 유도체 |
IL291391B (en) | 2012-11-15 | 2022-11-01 | Incyte Holdings Corp | Sustained release dosage forms of roxolitinib |
PT2964650T (pt) | 2013-03-06 | 2019-02-26 | Incyte Holdings Corp | Processos e intermediários para a preparação de um inibidor de jak |
SI3527263T1 (sl) | 2013-05-17 | 2021-05-31 | Incyte Corporation | Derivati bipirazola kot zaviralci JAK |
TWI503855B (zh) | 2013-07-05 | 2015-10-11 | Timotion Technology Co Ltd | 極限開關及具有該開關之線性致動器 |
MX2016001639A (es) | 2013-08-07 | 2016-10-07 | Incyte Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
AR097388A1 (es) | 2013-08-20 | 2016-03-09 | Incyte Corp | Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva |
KR20160136323A (ko) | 2014-02-28 | 2016-11-29 | 인사이트 코포레이션 | 골수형성이상증후군 치료용 jak1 억제제 |
LT3129021T (lt) | 2014-04-08 | 2020-12-10 | Incyte Corporation | B ląstelių piktybiškumo gydymas jak ir pi3k inhibitorių deriniu |
AU2015253192B2 (en) | 2014-04-30 | 2019-05-16 | Incyte Holdings Corporation | Processes of preparing a JAK1 inhibitor and new forms thereto |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
-
2008
- 2008-06-12 MX MX2009013402A patent/MX2009013402A/es active IP Right Grant
- 2008-06-12 MX MX2013005828A patent/MX342814B/es unknown
- 2008-06-12 ES ES08770794T patent/ES2467665T5/es active Active
- 2008-06-12 LT LTEP16152794.0T patent/LT3070090T/lt unknown
- 2008-06-12 EP EP18203965.1A patent/EP3495369B1/fr active Active
- 2008-06-12 DK DK08770794.9T patent/DK2173752T4/da active
- 2008-06-12 ME MEP-2009-345A patent/ME00960B/fr unknown
- 2008-06-12 ES ES18203965T patent/ES2903444T3/es active Active
- 2008-06-12 SG SG10201912675VA patent/SG10201912675VA/en unknown
- 2008-06-12 RS RS20160375A patent/RS54878B1/sr unknown
- 2008-06-12 ES ES13198120.1T patent/ES2575797T3/es active Active
- 2008-06-12 CN CN201310367212.9A patent/CN103524509B/zh active Active
- 2008-06-12 ES ES16152794T patent/ES2714092T3/es active Active
- 2008-06-12 BR BRPI0814254A patent/BRPI0814254B8/pt active IP Right Grant
- 2008-06-12 DK DK16152794.0T patent/DK3070090T3/en active
- 2008-06-12 EP EP13198120.1A patent/EP2740731B1/fr active Active
- 2008-06-12 AU AU2008266183A patent/AU2008266183B2/en active Active
- 2008-06-12 KR KR1020157002074A patent/KR20150036210A/ko active Search and Examination
- 2008-06-12 UA UAA201000232A patent/UA99467C2/ru unknown
- 2008-06-12 GE GEAP200811637A patent/GEP20125533B/en unknown
- 2008-06-12 PT PT87707949T patent/PT2173752E/pt unknown
- 2008-06-12 EP EP21200662.1A patent/EP4011883A1/fr active Pending
- 2008-06-12 TR TR2019/03488T patent/TR201903488T4/tr unknown
- 2008-06-12 RS RS20140152A patent/RS53245B2/sr unknown
- 2008-06-12 CA CA2689663A patent/CA2689663C/fr active Active
- 2008-06-12 PL PL16152794T patent/PL3070090T3/pl unknown
- 2008-06-12 CU CU20120155A patent/CU24179B1/es active IP Right Grant
- 2008-06-12 HU HUE16152794A patent/HUE043732T2/hu unknown
- 2008-06-12 KR KR1020107000805A patent/KR101549876B1/ko active IP Right Grant
- 2008-06-12 EA EA201070013A patent/EA019784B1/ru unknown
- 2008-06-12 US US12/137,892 patent/US20080312259A1/en not_active Abandoned
- 2008-06-12 PT PT16152794T patent/PT3070090T/pt unknown
- 2008-06-12 PL PL08770794.9T patent/PL2173752T5/pl unknown
- 2008-06-12 HU HUE13198120A patent/HUE029236T2/en unknown
- 2008-06-12 SI SI200831217T patent/SI2173752T2/sl unknown
- 2008-06-12 WO PCT/US2008/066662 patent/WO2008157208A2/fr active Application Filing
- 2008-06-12 DK DK13198120.1T patent/DK2740731T3/en active
- 2008-06-12 SI SI200832042T patent/SI3070090T1/sl unknown
- 2008-06-12 JP JP2010512343A patent/JP5475653B2/ja active Active
- 2008-06-12 RS RS20190251A patent/RS58449B1/sr unknown
- 2008-06-12 SI SI200831621A patent/SI2740731T1/sl unknown
- 2008-06-12 SG SG2012043428A patent/SG182198A1/en unknown
- 2008-06-12 PL PL13198120.1T patent/PL2740731T3/pl unknown
- 2008-06-12 MY MYPI20095311A patent/MY154969A/en unknown
- 2008-06-12 NZ NZ581803A patent/NZ581803A/en unknown
- 2008-06-12 SG SG10201509887UA patent/SG10201509887UA/en unknown
- 2008-06-12 EP EP08770794.9A patent/EP2173752B2/fr active Active
- 2008-06-12 EP EP16152794.0A patent/EP3070090B1/fr not_active Revoked
- 2008-06-12 CN CN2008801029033A patent/CN101932582B/zh active Active
-
2009
- 2009-12-06 IL IL202524A patent/IL202524A/en active IP Right Grant
- 2009-12-09 CR CR11151A patent/CR11151A/es unknown
- 2009-12-10 DO DO2009000280A patent/DOP2009000280A/es unknown
- 2009-12-10 TN TNP2009000514A patent/TN2009000514A1/fr unknown
- 2009-12-10 GT GT200900314A patent/GT200900314A/es unknown
- 2009-12-10 ZA ZA2009/08826A patent/ZA200908826B/en unknown
- 2009-12-11 CU CU2009000213A patent/CU23933B1/es active IP Right Grant
- 2009-12-11 NI NI200900216A patent/NI200900216A/es unknown
- 2009-12-14 EC EC2009009802A patent/ECSP099802A/es unknown
- 2009-12-16 CO CO09144142A patent/CO6251256A2/es active IP Right Grant
-
2010
- 2010-01-08 SM SM201000002T patent/SMP201000002B/it unknown
- 2010-01-12 MA MA32505A patent/MA31517B1/fr unknown
- 2010-10-14 HK HK10109728.8A patent/HK1143161A1/xx unknown
-
2013
- 2013-12-05 US US14/097,588 patent/US8722693B2/en active Active
- 2013-12-05 US US14/097,598 patent/US20140094477A1/en not_active Abandoned
-
2014
- 2014-04-18 US US14/256,383 patent/US8822481B1/en active Active
- 2014-04-18 US US14/256,311 patent/US8829013B1/en active Active
- 2014-05-01 IL IL232410A patent/IL232410A0/en active IP Right Grant
- 2014-05-06 US US14/270,915 patent/US9376439B2/en active Active
- 2014-05-07 CY CY20141100323T patent/CY1115145T1/el unknown
- 2014-06-09 HR HRP20140541TT patent/HRP20140541T4/hr unknown
- 2014-12-03 HK HK14112206.9A patent/HK1198652A1/zh unknown
-
2016
- 2016-05-25 US US15/164,518 patent/US10016429B2/en active Active
- 2016-06-13 CY CY20161100513T patent/CY1117693T1/el unknown
- 2016-06-21 HR HRP20160717TT patent/HRP20160717T1/hr unknown
-
2018
- 2018-06-08 US US16/003,210 patent/US10610530B2/en active Active
-
2019
- 2019-01-16 IL IL264276A patent/IL264276B/en active IP Right Grant
- 2019-02-28 HR HRP20190385TT patent/HRP20190385T1/hr unknown
- 2019-03-07 CY CY20191100273T patent/CY1121338T1/el unknown
- 2019-06-11 NO NO2019025C patent/NO2019025I1/no unknown
-
2020
- 2020-03-02 US US16/806,244 patent/US11213528B2/en active Active
-
2021
- 2021-01-26 IL IL280401A patent/IL280401B/en unknown
- 2021-10-31 IL IL287708A patent/IL287708B1/en unknown
- 2021-11-29 US US17/536,925 patent/US20220288078A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31517B1 (fr) | Sels de l'inhibiteur (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile de la janus kinase | |
MX2009013403A (es) | Metabolitos del inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3 -d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo. | |
WO2008005956A3 (fr) | Inhibiteurs de pyrrolotriazine kinase | |
BRPI0619817B8 (pt) | composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição | |
ES2354824T3 (es) | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas. | |
MX2010005300A (es) | 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus. | |
SG166828A1 (en) | Aminopyrimidines useful as kinase inhibitors | |
MY139689A (en) | Imidazotriazines as protein kinase inhibitors | |
DE602006004844D1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
LU91407I2 (fr) | Sunitinib optionnellement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel l-malate (sutent) | |
ATE542814T1 (de) | Pyrazinkinaseinhibitoren | |
MA35858B1 (fr) | Nouvelles formes et sels d'un inhibiteur de l'aldostérone synthase imidazole dihydropyrrolo [1,2-c] ou ou de l'inhibiteur de l'aromatase | |
TH124674B (th) | เมทาโบไลท์ของสารยับยั้งจานัสไคเนส (R)-3-(4-(7H-ไพร์โรโล[2,3-d]ไพริมิดิน-4-อิล)-1H-ไพราซอล-1-อิล)-3-ไซโคลเพนทิลโพรเพนไนไทรล์ |